KLF2 and cardiovascular disorder: Given the nexus of flow-dependent endothelial function and the KLF2 transcriptional program in endothelial cells, it would seem logical that GPCRs exist on the surface of the endothelium that can potentially regulate the KLF2 transcriptional program and therefore represent attractive and druggable targets for development of novel therapeutics to treat cardiovascular disease through enhancing and maintaining a healthy endothelial phenotype.